India
· Delayed Price · Currency is INR | Market Cap | 931.37B |
| Revenue (ttm) | 232.42B |
| Net Income (ttm) | 45.26B |
| Shares Out | 1.01B |
| EPS (ttm) | 44.97 |
| PE Ratio | 20.58 |
| Forward PE | 20.52 |
| Dividend | 11.00 (1.20%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 184,479 |
| Average Volume | 1,026,342 |
| Open | 932.00 |
| Previous Close | 925.60 |
| Day's Range | 924.50 - 934.00 |
| 52-Week Range | 795.00 - 1,324.30 |
| Beta | 0.47 |
| RSI | 61.91 |
| Earnings Date | May 16, 2025 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management... [Read more]
Financial Performance
In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.
Financial StatementsNews
Zydus share price: Nomura sees 29% upside, upbeat on US growth and vaccine contribution
Nomura has retained its buy rating on Zydus Lifesciences with a target price of ₹1,140, implying an upside of nearly 29% from the current market price of ₹884.45. The brokerage acknowledges a Q4 EBITD...
Zydus Lifesciences FY 25 net profit rises 17%; co declares Rs 11 dividend
Zydus Lifesciences reported a 17.3% increase in FY25 consolidated net profit, reaching Rs 4,525.5 crore, driven by strong US and India sales. The US formulations business stood out with a 27.2% growth...
Zydus Lifesciences Q4 results: Revenue rises 18% YoY; Net profit flat at Rs 1,171 crore
Zydus Lifesciences reported a marginal decline in net profit for the fourth quarter ended March 31, 2025. The company posted a consolidated net profit of ₹1,171 crore, down from ₹1,182 crore in the co...
Q4 Results Today, May 20: NHPC, Dixon Technologies, Gland Pharma, Zydus Lifesciences, Hindalco among companies reporting earnings
A total of 146 companies are scheduled to release their financial results for the January-March quarter on Tuesday, May 20. These earnings reports will provide insight into the performance of these fi...
Zydus receives EIR from USFDA for its Ambernath API manufacturing facility
Zydus Lifesciences Ltd. has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API...
Zydus gets USFDA nod for generic version of Copaxone for treatment of Multiple Sclerosis
Zydus Lifesciences Limited announced on Thursday that it has received final approval from the United States Food and Drug Administration (USFDA) for its Glatiramer Acetate Injection, a generic version...
Zydus gets USFDA final approval for Niacin Extended-Release Tablets
Zydus Lifesciences Limited, along with its subsidiaries and affiliates (collectively referred to as “Zydus”), has received final approval from the United States Food and Drug Administration (USFDA) to...
Stocks to watch on April 28: Force Motors, Jayaswal Neco, NRB Bearings, Titan, Reliance Industries, Zydus Lifesciences in focus
Stocks are likely to see active trading on April 28 after several companies reported their Q4FY25 earnings and corporate announcements. Here’s a quick look: Positive developments: Jayaswal Neco report...
Zydus Lifesciences receives 6 observations from USFDA for Gujarat API unit
India-Business News: Zydus Lifesciences on Saturday said it received six observations from the US Food and Drug Administration (USFDA) following a surveillance inspection .
Zydus Lifesciences receives 6 observations in USFDA inspection at API unit in Dabhasa, Gujarat
Zydus Lifesciences has recently undergone a USFDA surveillance inspection at its Active Pharmaceutical Ingredient (API) manufacturing unit located in Dabhasa, Gujarat. The inspection, conducted from A...
Zydus Medtech, Braile Biomedica sign global licensing pact to commercialise advanced TAVI technology
Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences, has entered into a strategic global licensing agreement with Brazil-based Braile Biomedica to commercialise its cutting-...
Zydus Lifesciences confirms losing US patent case to Astellas in mirabegron litigation
Zydus Lifesciences Ltd announced that the United States District Court for the District of Delaware has ruled in favor of Astellas Pharma Inc., upholding the validity of the Japanese drugmaker’s US Pa...
Zydus Lifesciences shareholder commitments in tender offer for Amplitude Surgical
Zydus Lifesciences Limited has announced the execution of undertakings from seven shareholders to tender a total of 2,236,911 shares of Amplitude Surgical SA. These shares represent approximately 4.7%...
Zydus down 5%, Lupin down nearly 4% as US court orders withdrawal of Myrbetriq drug
Shares of Zydus Lifesciences and Lupin plunged sharply on April 16 after both companies lost a patent litigation case related to the bladder treatment drug Myrbetriq in the United States. The US Feder...
Zydus Lifesciences shares drop over 2.5% after losing Myrbetriq patent case in US
Shares of Zydus Lifesciences Ltd fell sharply by 2.63% to ₹859.95 during Tuesday’s trade following a major legal setback in the US. The stock dropped from a previous close of ₹883.15, reacting negativ...
Stocks to watch today: Zydus, Aurobindo, HCL Tech, Tata Power, Indian Hotels, Cyient in focus on expansion and global deals
Stocks of several companies are expected to remain in the spotlight today following a series of announcements related to international expansion, regulatory approvals, and strategic partnerships. Zydu...
Top Stocks to watch on April 15: Ircon, Zydus, Ashoka Buildcon, Tata Power, Macrotech, Cyient in focus as markets reopen after long weekend
Indian stock markets reopen after the Monday holiday (April 14) for Dr. Baba Saheb Ambedkar Jayanti. Here are the key stocks to watch: Ircon International Secured a Letter of Acceptance worth ₹127 cro...
Zydus Lifesciences receives USFDA approval for Jaythari (Deflazacort) Tablets across four strengths
Zydus Lifesciences Limited has announced that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market its Jaythari® (Deflazacort) tablets i...
Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’
Indian pharmaceutical stocks declined in early trade on Wednesday following renewed concerns over potential U.S. import tariffs. At 9:36 AM, Aurobindo Pharma shares were down 2% to ₹1,073.15, Dr. Redd...
Zydus Lifesciences shares fall nearly 7% as Trump signals potential pharma tariffs
Shares of Zydus Lifesciences Ltd declined 6.92% to ₹839.50 on Friday, falling ₹62.40 from the previous close of ₹901.90, as concerns escalated over the potential imposition of U.S. tariffs on pharmace...
Zydus Lifesciences shares jump 5.25% as U.S. spares pharma exports from 26% tariff
Shares of Zydus Lifesciences Ltd surged 5.25% to ₹937.95 on April 3, emerging as one of the top gainers in early trade, after U.S. President Donald Trump’s reciprocal tariff policy excluded pharmaceut...
Top stocks to buy today: Stock recommendations for March 21, 2025
Stock market recommendations: Bajaj Broking Research recommends Zydus Lifesciences and National Aluminium stocks for today. It expects Nifty to move towards 23,500 levels and sees Bank Nifty heading t...
Zydus shares nearly jump 3% on USFDA approval for Apalutamide Tablets
Zydus Lifesciences Ltd saw nearly 3% surge in its stock price after securing final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Apalutamide Tablets, 60 mg, in ...
Zydus receives U.S. FDA nod for 60 mg Apalutamide Tablets
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Apalutamide Tablets, 60 mg (Erleada® Tablets, 60 mg) in the...
Zydus Lifesciences shares up 2% as USFDA grants approval for Eluxadoline tablets
Shares of Zydus Lifesciences Ltd (NSE:ZYDU) surged 2% after the company received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Eluxadoline Tablets (75 mg ...